ReviewAsian journal of pharmaceutical sciences2018
Exosome-based small RNA delivery: Progress and prospects.
Review in Asian journal of pharmaceutical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Electrical Stimulation-Induced Modulation of Small Extracellular Vesicles in Regenerative Therapy.Tissue engineering and regenerative medicine · 2026Review
- LPS/TLR4-activated M1-polarized macrophage-derived exosomes enhance IBV vaccine efficacy in chickens.Journal of virology · 2025Article
- Clinical implications of miR-195 in cancer: mechanisms, potential applications, and therapeutic strategies.Journal of cancer research and clinical oncology · 2025Review
- Bioinspired Extracellular Vesicles for Enhanced Delivery of siRNA to Tumors.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Nature's carriers: leveraging extracellular vesicles for targeted drug delivery.Drug delivery · 2024Review
- Review
- RNA therapeutics in targeting G protein-coupled receptors: Recent advances and challenges.Molecular therapy. Nucleic acids · 2024Review
- Proteomic profiling of extracellular vesicles derived from human serum for the discovery of biomarkers in Avascular necrosis.Clinical proteomics · 2024Article
- Review
- Extracellular Vesicles in Therapeutics: A Comprehensive Review on Applications, Challenges, and Clinical Progress.Pharmaceutics · 2024Review
- miRNA-Based Technologies in Cancer Therapy.Journal of personalized medicine · 2023Review
- Engineered small extracellular vesicle-mediated NOX4 siRNA delivery for targeted therapy of cardiac hypertrophy.Journal of extracellular vesicles · 2023Article
- Antitumor synergism between PAK4 silencing and immunogenic phototherapy of engineered extracellular vesicles.Acta pharmaceutica Sinica. B · 2023Article
- Therapeutic effects of engineered exosome-based miR-25 and miR-181a treatment in spinocerebellar ataxia type 3 mice by silencing ATXN3.Molecular medicine (Cambridge, Mass.) · 2023Article
- Exosome-mediated delivery of gga-miR-20a-5p regulates immune response of chicken macrophages by targeting IFNGR2, MAPK1, MAP3K5, and MAP3K14.Animal bioscience · 2023Article
- RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.The Journal of pharmacology and experimental therapeutics · 2023Review
- The physiological functions and therapeutic potential of exosomes during the development and treatment of polycystic ovary syndrome.Frontiers in physiology · 2023Review
- MKL-1 suppresses ferroptosis by activating system Xc- and increasing glutathione synthesis.International journal of biological sciences · 2023Article
- The Therapeutic Potential and Clinical Significance of Exosomes as Carriers of Drug Delivery System.Pharmaceutics · 2022Review
- Tumor endothelial cell-derived extracellular vesicles contribute to tumor microenvironment remodeling.Cell communication and signaling : CCS · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA interfering (RNAi), mediated by small interfering RNAs and microRNAs, is currently one of the most promising tools of gene therapy. Small RNAs are capable of inducing specific post-transcriptional gene silencing, providing a potentially effective platform for the treatment of a wide array of diseases. However, similar to other nucleic acid-based drugs, the major hurdle of RNAi therapy is lack of efficient and non-immunogenic delivery vehicles. Currently, viruses, synthetic polymers, and lipid-based carriers are among the most widely studied vehicles for small RNA delivery. However, many drawbacks are reported to be associated with these delivery vehicles. There is a pressing need to replace them with more efficient and better-tolerated approaches. Exosomes secreted from the endocytic compartment of live cells, are a subtype of endogenous extracellular vesicles that transfer genetic and biochemical information among different cells, thus playing an important role in cell-cell communication. Recently, accumulating attention has been focused on harnessing exosomes as nanaocarriers for small RNAs delivery. Due to their natural role in shuttling endogenous nucleic acid in our body, exosomes may exhibit higher delivery efficiency, lower immunogenicity, and better compatibility than existing foreign RNA carriers. Importantly, exosomes own intrinsic homing capacity that can guide small RNAs across natural membranous barriers. Moreover, such a capacity can be further improved by adding appropriate targeting moieties. In this manuscript, we briefly review the progress and challenges of RNAi therapy, and discuss the potential of exosomes' applications in small RNA delivery with focus on the most recent advances in exosome-based small RNA delivery for disease therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.